ClinicalTrials.gg
Active, not recruitingNCT04980833EPIK-P3Updated Oct 14, 2026

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

A Phase 2 interventional study of Alpelisib in PIK3CA-related Overgrowth Spectrum (PROS), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 2 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Updated Oct 14, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
2 Years to 100 Years
Sex
All
01

Study summary

This Phase II, multicenter, open-label study, preceded by a retrospective non-interventional period, is assessing the long-term safety and efficacy of alpelisib in pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS).

Read the detailed description

The study will enroll male and female participants aged 2 years or older who previously participated in the EPIK-P1 study (NCT04285723) and continued to receive alpelisib after the EPIK-P1 data cut-off date of 09 March 2020.

The study consists of an initial retrospective period followed by a prospective period.

The retrospective, non-interventional period began on 10 March 2020, one day after the EPIK-P1 data cut-off date, and ended the day before the participant received the first interventional dose of alpelisib in the prospective period. Safety and efficacy data collected during routine medical practice were longitudinally abstracted from participants' medical records.

The prospective, interventional period began on the day the participant received the first interventional dose of alpelisib. Safety and efficacy data are being collected according to a structured assessment plan common to all participants. The prospective period will end after all participants have completed at least 5 years of treatment or discontinued treatment earlier, whichever occurs first.

02

Conditions studied

  • PIK3CA-related Overgrowth Spectrum (PROS)

Keywords

  • PIK3CA-Related Overgrowth Spectrum (PROS)
  • Alpelisib
  • BYL719
  • PIK3CA Mutation
  • Overgrowth Disorders
  • Adult
  • Pediatric
  • Phase II
  • Long-term Safety
  • Long-term Efficacy
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who had previously participated in the study EPIK-P1.
  • Signed form and assent (when applicable) from the participant, parent, or guardian must be obtained prior to any study related screening procedures being performed.
  • Participant is treated with at least one dose of alpelisib after the EPIK-P1 study data cut- off date of 09-Mar-2020.

Exclusion criteria

Exclusion Criteria:

For participants in the retrospective period

- All EPIK-P1 participants who permanently discontinued the drug on or prior to the cut-off date 09-Mar-2020.

For participants in the prospective period

  • Previous alpelisib treatment discontinuation (after 09-Mar-2020) due to any of the following adverse events:

    • Grade 4 skin and subcutaneous tissue disorders
    • Stevens-Johnson-Syndrome (SJS)/ Toxic Epidermal Necrolysis (TEN) or other SJS/TEN-like severe skin reactions (any grade)
    • Grade 4 hyperglycemia without confounding factors
    • Pneumonitis (any grade)
    • Grade 4 stomatitis
    • Grade 4 pancreatitis
    • Recurrent grade 4 thrombocytopenia
    • Grade 3 or 4 serum creatinine increase
    • Grade 4 isolated total elevation
    • Recurrent grade 3 or 4 corrected by Fridericia's formula prolongation (>500 ms or >60 ms change from baseline)
  • Known impairment of GI function due to concomitant disease that may significantly alter the absorption of the study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) at time of .
  • Participant with uncontrolled diabetes mellitus (Type I or II) at time of informed consent.

Other inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Alpelisib

    All participants receive alpelisib orally once daily during the prospective period. Treatment is planned for at least 5 years or until earlier discontinuation.

    Drug: Alpelisib

Interventions

  • Retrospective period: Participants receive alpelisib under a Temporary Authorization for Use (ATU) or Managed Access Program (MAP) according to the treatment plan established by the treating physician. The recommended starting dose is 50 mg orally once daily for pediatric participants and 250 mg orally once daily for adult participants. Pediatric treatment interruptions and adult dose adjustments are permitted for toxicity. Prospective period: Participants receive alpelisib orally once daily with food. The starting dose is generally based on the last dose received during the retrospective period. Participants transitioning from fasted to fed administration may start at an adjusted dose. Dose escalation for response optimization and dose reduction or interruption for safety or tolerability are permitted. Dose escalation above 250 mg is not allowed. Treatment is planned for at least 5 years or until earlier discontinuation.

    Also known as: BYL719

06

What researchers measure

Primary outcomes

  1. Prospective period only: Proportion of participants with new or worsening grade ≥3 treatment emergent adverse events (AEs)

    Incidence of new or worsening grade ≥3 treatment emergent AEs (by system organ class and preferred term)

    Time frame: From first interventional dose administration in the prospective period (Day 1) until treatment discontinuation, assessed for at least 5 years; participants not entering a Novartis rollover study undergo a 30-day safety follow-up after the last dose.

Secondary outcomes

  1. Retrospective period: Proportion of participants with Adverse Events (AEs)

    Incidence, type and severity per CTCAE v4.03 criteria, causality assessments of AEs, including changes in laboratory values, vital signs and cardiac function during the retrospective period.

    Time frame: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period (Day -1)

  2. Prospective period: Proportion of participants with AEs

    Incidence, type and severity per CTCAE v4.03 criteria, causality assessments of AEs, including changes in laboratory values, vital signs, cardiac function, and growth, sexual maturation, and bone/dental development (for applicable ages).

    Time frame: From first interventional dose administration in the prospective period (Day 1) until treatment discontinuation, assessed for at least 5 years

  3. Retrospective and prospective period: Overall clinical assessment as assessed by the investigator

    Proportion of participants with overall clinical assessment reported as improvement, stable or worsened, as assessed by the investigator.

    Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years.

  4. Retrospective and prospective period: Incidence of PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities.

    Incidence of symptoms and complications/comorbidities associated with PROS among affected participants.

    Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years.

  5. Retrospective and prospective period: Proportion of participants with healthcare visits/hospitalizations due to PROS.

    Proportion of participants with healthcare visits/hospitalizations due to PROS.

    Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years

  6. Retrospective and prospective period: Proportion of participants requiring PROS-related treatment(s) other than alpelisib

    Proportion of participants requiring PROS-related treatment(s) other than alpelisib, including medications (concomitant PROS-related medications including medication for the management of PROS related complications as well as medications to manage complications secondary to alpelisib) and non-drug treatments (e.g., feeding tube, ketogenic diet, non-invasive device for sleep apnea, sclerotherapy, endovascular occlusive procedures)

    Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years

  7. Retrospective and prospective period: Proportion of participants with dose adjustments of alpelisib

    Proportion of participants requiring dose increase, reductions and interruptions of alpelisib

    Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years

  8. Retrospective and prospective period: Proportion of participants with PROS-related surgeries

    Proportion of participants requiring surgery due to PROS

    Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years

07

Study locations

6 sites
  • Boston Childrens Hospital
    Boston, Massachusetts 02215, United States
  • Novartis Investigative Site
    Dijon, 21000, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Dublin, 12, Ireland
  • Novartis Investigative Site
    Madrid, 28046, Spain
08

References and documents

Publications

  • Cheng YL, Bustamante D, Yates DM, Menendez S, Chi AC. TEK-related venous malformation of the orofacial region: report of a case with multidisciplinary treatment guided by molecular diagnosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2025 Nov;140(5):587-593. doi: 10.1016/j.oooo.2025.05.009. Epub 2025 Jun 6. PubMed 40603171 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2022 (actual). Primary completion is estimated for Jun 2027, 64 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Aug 2027 → Jun 2027 and completion Aug 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2021
First posted
Jul 28, 2021
StartActual
Jan 27, 2022
Primary completionEst.
Jun 22, 2027was Aug 2027
CompletionEst.
Jun 22, 2027was Aug 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 20, 2027→Jun 22, 2027
Oct 14, 2026
Study completion
Aug 20, 2027→Jun 22, 2027
Oct 14, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameProspective period only: Proportion of participants with new or worsening grade ≥3 treatment emergent adverse events (AEs)From date of first interventional dose administration in the prospective period (Day 1) to 30 days after last dose of study drug, assessed up to 5 years. → From first interventional dose administration in the prospective period (Day 1) until treatment discontinuation, assessed for at least 5 years; participants not entering a Novartis rollover study undergo a 30-day safety follow-up after the last dose.
Oct 14, 2026
Secondary outcomes
8 time frame changed, 4 description edited
What changed in the outcomes
  • Time frameRetrospective period: Proportion of participants with Adverse Events (AEs)From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1) → From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period (Day -1)
  • Time frameProspective period: Proportion of participants with AEsFrom Day 1 up to 5 years → From first interventional dose administration in the prospective period (Day 1) until treatment discontinuation, assessed for at least 5 years
  • Time frameRetrospective and prospective period: Overall clinical assessment as assessed by the investigatorRetrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years.
  • Time frameRetrospective and prospective period: Incidence of PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities.Retrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years.
  • Time frameRetrospective and prospective period: Proportion of participants with healthcare visits/hospitalizations due to PROS.Retrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
  • Time frameRetrospective and prospective period: Proportion of participants requiring PROS-related treatment(s) other than alpelisibRetrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
  • Time frameRetrospective and prospective period: Proportion of participants with dose adjustments of alpelisibRetrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
  • Time frameRetrospective and prospective period: Proportion of participants with PROS-related surgeriesRetrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
  • DescriptionProspective period: Proportion of participants with AEs: how it is measured was reworded
  • DescriptionRetrospective and prospective period: Incidence of PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities.: how it is measured was reworded
  • DescriptionRetrospective and prospective period: Proportion of participants with healthcare visits/hospitalizations due to PROS.: how it is measured was reworded
  • DescriptionRetrospective period: Proportion of participants with Adverse Events (AEs): how it is measured was reworded
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Aug 20, 2027→Jun 22, 2027
    Study completion Aug 20, 2027→Jun 22, 2027
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameProspective period only: Proportion of participants with new or worsening grade ≥3 treatment emergent adverse events (AEs)From date of first interventional dose administration in the prospective period (Day 1) to 30 days after last dose of study drug, assessed up to 5 years. → From first interventional dose administration in the prospective period (Day 1) until treatment discontinuation, assessed for at least 5 years; participants not entering a Novartis rollover study undergo a 30-day safety follow-up after the last dose.
    Secondary outcomes 8 time frame changed, 4 description edited
    What changed in the outcomes
    • Time frameRetrospective period: Proportion of participants with Adverse Events (AEs)From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1) → From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period (Day -1)
    • Time frameProspective period: Proportion of participants with AEsFrom Day 1 up to 5 years → From first interventional dose administration in the prospective period (Day 1) until treatment discontinuation, assessed for at least 5 years
    • Time frameRetrospective and prospective period: Overall clinical assessment as assessed by the investigatorRetrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years.
    • Time frameRetrospective and prospective period: Incidence of PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities.Retrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years.
    • Time frameRetrospective and prospective period: Proportion of participants with healthcare visits/hospitalizations due to PROS.Retrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
    • Time frameRetrospective and prospective period: Proportion of participants requiring PROS-related treatment(s) other than alpelisibRetrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
    • Time frameRetrospective and prospective period: Proportion of participants with dose adjustments of alpelisibRetrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
    • Time frameRetrospective and prospective period: Proportion of participants with PROS-related surgeriesRetrospective: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period of this study (Day -1). Prospective: From Day 1 up to 5 years → Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
    • DescriptionProspective period: Proportion of participants with AEs: how it is measured was reworded
    • DescriptionRetrospective and prospective period: Incidence of PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities.: how it is measured was reworded
    • DescriptionRetrospective and prospective period: Proportion of participants with healthcare visits/hospitalizations due to PROS.: how it is measured was reworded
    • DescriptionRetrospective period: Proportion of participants with Adverse Events (AEs): how it is measured was reworded
    + 5 other changes: identifiers, verification date, description, conditions and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04980833
Responsible party
Sponsor
First posted
Jul 28, 2021
Start date
Jan 27, 2022
Primary completion
Jun 22, 2027 (estimated)
Completion
Jun 22, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpelisib

Start the discussion